Clinical trial · Interventional
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
NCT06565247CI-TRIAL-00086763recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this trial the connection between image properties (mpMRI and PSMA-PET) and tissue properties (molecular and histopathology) will be investigated in order to improve diagnostics and image-based treatment guidance of prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]PSMA-PET | Drug | — | UNRESOLVED |
| MRI sequences optimized for prostate cancer examinations | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pre-surgical imaging of high-risk prostate cancer using [18F]PSMA-PET/mpMRI or mpMRI
- description
- One-time pre-surgical imaging using \[18F\]PSMA-PET/mpMRI (at Umea University Hosptial) or mpMRI (at Skåne University Hospital)
- interventionNames
- Drug: [18F]PSMA-PET
- Device: MRI sequences optimized for prostate cancer examinations
Primary outcomes (1)
- measure
- Accuracy of PSMA-PET and mpMRI for identification and delineation of intraprostatic lesions
- timeFrame
- Pre-surgical imaging 1-6 weeks before surgery vs. post-surgery histopathology as performed within 1-4 weeks for normal clinical work-up. Within the 5-year time frame of the study, analyses will be complemented with detailed study specific histopathology
- description
- Spatially defined aggressive PC lesions, or subparts of lesion, identified and defined using PSMA-PET and/or mpMRI compared to histopathology.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed prostate cancer planned to be treated with radical prostatectomy 2. PSMA-PET/CT conducted as part of the clinical management for the existing prostate cancer. 3. ≥4 weeks since last biopsy of the prostate 4. One or more of the following criteria 1. cT3, or high suspicion of extra prostatic growth on mpMRI 2. Gleason score ≥8 3. PSA 20-49 ng/ml 5. \>18 years 6. Given a written consent to participate in the trial Exclusion Criteria: 1. Non-MR-safe implants or another contraindication to MRI or PET 2. Claustrophobia 3. Unfit for MRI or PET/MRI examination for any other reason, e.g., back pain 4. WHO PS \>1 5. Patients treated with neoadjuvant/concomitant anti-testosterone treatment (surgical or medical castration or anti-androgens) 6. TUR-P within 6 months 7. Metastatic disease in skeleton, parenchymal organs, or lymph nodes outside the pelvis. 8. Patients with previous diagnosis of other malignant disease. Exceptions could be made for basal cell carcinoma of the skin or progression free survival at least 10 years after any previous tumour. 9. Creatinine clearance \< 30ml/min (acc. to http://www.fass.se/LIF/produktfakta-/kreatinin.jsp) 10. Tinnitus or severe hearing loss
References
Publications (0)
Data not yet available
No reference posted for this study.